BNTX Stock Recent News

A meeting of the Food and Drug Administration's vaccine advisory committee to discuss the next season's flu vaccine has reportedly been canceled, the second such disruption of a meeting involving vaccine policy experts at the federal level since prominent vaccine skeptic Robert F. Kennedy Jr took over as the Health and Human Services secretary earlier this month.

Stocks of MRNA, PFE, NVAX and BNTX rose in anticipation that a new virus in China could trigger another pandemic.

MAINZ, Germany, February 24, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the fourth quarter and full year 2024 on Monday, March 10, 2025. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EDT (1:00 p.m. CET) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update.

BioNTech (BNTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Shares of vaccine makers and packaged food companies fell on Tuesday after President Donald Trump's pick for U.S. health secretary, Robert F. Kennedy Jr., moved closer to the job after a favorable vote by a Senate panel.

Shares of vaccine companies fell after a Senate panel voted to advance Robert F. Kennedy Jr.'s nomination to lead the Department of Health and Human Services to the full chamber.

MAINZ, Germany, February 3, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today the completion of the acquisition of Biotheus (“Biotheus”), a clinical-stage biotechnology company dedicated to the discovery and development of novel antibodies to address unmet medical needs of patients with oncological or inflammatory diseases. The acquisition was announced on November 2024 and builds on the successful collaboration on the late-stage clinical asset BNT327, an investigational bispecific antibody targeting PD-L1 and VEGF-A, and other bispecific antibody candidates.

How expensive is the stock market right now? The S&P 500 Shiller CAPE ratio is near its second-highest level ever.

The average of price targets set by Wall Street analysts indicates a potential upside of 25.6% in BioNTech (BNTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

MAINZ, Germany, January 14, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today will present its 2025 strategic priorities and progress on the Company's pipeline of mRNA therapeutics, immunomodulators, and targeted therapies at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California.